Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis (SAFESYNC NG)

16. November 2026 aktualisiert von: Braile Biomedica Ind. Com. e Repr. Ltda.

Evaluation of the Safety and Clinical Performance of the Next-Generation SAFESYNC Balloon-Expandable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis: A Prospective, Multicenter, Single-Arm Pivotal Study

This pivotal, prospective, multicenter (Brazil, Chile and Argentina), single-arm study will evaluate the safety and clinical performance of the Inovare® Safesync Next-Generation bioprosthetic heart valve, implanted by transfemoral transcatheter aortic valve implantation (TAVI) with the B-Delivery System, in patients aged 70 years or older with severe aortic stenosis and an indication for TAVI, regardless of surgical risk. The study will enroll 210 participants.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

210

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Clinical Research Department - Braile Biomédica
  • Telefonnummer: +5517 21367000
  • E-Mail: pesquisa@braile.com.br

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

70 Jahre und älter (Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

Severe aortic valve stenosis diagnosed according to criteria established in current guidelines; Age ≥70 years, regardless of surgical risk; Indication for transcatheter aortic valve implantation (TAVI); Willing to participate and to sign the written informed consent form.

Exclusion Criteria:

Any condition considered a contraindication to implantation of a bioprosthetic heart valve (e.g., patient with an indication for a mechanical heart valve);

Known hypersensitivity or contraindication to any of the following that cannot be adequately managed with premedication:

  1. Aspirin, clopidogrel, or heparin (heparin-induced thrombocytopenia [HIT] or heparin-induced thrombocytopenia with thrombosis [HITTS]);
  2. Nitinol (titanium or nickel);
  3. Contrast media; Blood dyscrasias: leukopenia (white blood cell count <1,000/mm³), thrombocytopenia (platelet count <100,000 cells/mm³), history of coagulopathy, or hypercoagulable states; Active infection, including endocarditis; Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or need for mechanical hemodynamic support; Recent stroke or transient ischemic attack (within 6 months); History of gastrointestinal bleeding or other bleeding that precludes anticoagulant or antiplatelet therapy; Estimated life expectancy of less than 5 years; Other medical, social, or psychological conditions that, in the investigator's opinion, prevent the patient from providing consent or adequately complying with the protocol; Pre-existing prosthetic heart valve in the aortic position (biological or mechanical); Concomitant severe mitral or tricuspid valve disease; Hypertrophic obstructive cardiomyopathy; Percutaneous coronary intervention performed within 72 hours prior to the study procedure; Femoral artery diameter <5.5 mm (for Safesync 20 to 24 mm), <6.0 mm (for Safesync 26 and 28 mm), or <6.5 mm (for Safesync 30 mm); High risk of annular rupture or significant residual paravalvular leak due to severe calcification of the aortic valve or left ventricular outflow tract; High risk of coronary obstruction (coronary ostial height <10 mm with narrow sinuses of Valsalva [SOV], defined as a mean SOV diameter <3 mm larger than the bioprosthesis size), as determined by computed tomography angiography; Left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤30%; Severe chronic kidney disease, defined as glomerular filtration rate <30 mL/min/1.73 m².

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: INOVARE® SAFESYNC Next-Generation TAVI

Participants will undergo TAVI via transfemoral access using the INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve and the B-Delivery System.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Device Success According to VARC-3 Criteria
Zeitfenster: 30 days after the procedure

Technical success; Absence of mortality; Absence of surgery or intervention related to the device or to major vascular, access-related, or cardiac structural complications; Intended valve performance, defined as mean transvalvular gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation.

30 days after the procedure

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants Achieving Technical Success According to VARC-3 Criteria
Zeitfenster: During the procedure

Defined as freedom from mortality; successful vascular access, delivery of the device, and retrieval of the delivery system; correct positioning of a single prosthetic heart valve in the intended anatomical location; and freedom from surgery or intervention related to the device or to a major vascular, access-related, or cardiac structural complication. Results will be reported as the number and percentage of participants achieving technical success.

During the procedure
Incidence and Severity of Paravalvular Leak
Zeitfenster: 30 days, 6 months, 12 months, and annually through 5 years

Paravalvular leak will be assessed by transthoracic echocardiography and classified according to severity. The number and percentage of participants with paravalvular leak in each severity category will be reported.

30 days, 6 months, 12 months, and annually through 5 years
Mean Transvalvular Aortic Pressure Gradient Assessed
Zeitfenster: 30 days, 6 months, 12 months, and annually through 5 years

Mean transvalvular aortic pressure gradient will be assessed by transthoracic echocardiography and reported in mmHg.

30 days, 6 months, 12 months, and annually through 5 years
Distribution of Participants by New York Heart Association Functional Class
Zeitfenster: 30 days, 6 months, 12 months, and annually through 5 years

Functional status will be assessed using the New York Heart Association (NYHA) Functional Classification. The classification ranges from Class I to Class IV, where Class I represents no limitation of physical activity and Class IV represents inability to perform physical activity without symptoms and/or symptoms at rest. Higher NYHA classes indicate worse functional status. Results will be reported as the number and percentage of participants in each NYHA functional class.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of New Permanent Pacemaker Implantation
Zeitfenster: 30 days, 6 months, 12 months, and annually through 5 years

New permanent pacemaker implantation following the index transcatheter aortic valve implantation procedure will be assessed. Results will be reported as the number and percentage of participants who undergo new permanent pacemaker implantation.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of All-Cause Mortality
Zeitfenster: 30 days, 6 months, 12 months, and annually through 5 years

All-cause mortality will be assessed throughout follow-up. Results will be reported as the number and percentage of participants who die from any cause.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Stroke
Zeitfenster: 30 days, 6 months, 12 months, and annually through 5 years

Stroke events will be assessed based on clinical neurological evaluation and classified according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants experiencing stroke.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Bioprosthetic Valve-Related Reintervention
Zeitfenster: 30 days, 6 months, 12 months, and annually through 5 years

Bioprosthetic valve-related reintervention will be defined as any surgical or transcatheter intervention performed to treat dysfunction or failure of the implanted study valve. Results will be reported as the number and percentage of participants undergoing valve-related reintervention.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Bioprosthetic Valve Dysfunction According to VARC-3 Definitions
Zeitfenster: 30 days, 6 months, 12 months, and annually through 5 years

Bioprosthetic valve dysfunction will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Bioprosthetic valve dysfunction includes structural valve deterioration, non-structural valve dysfunction, valve thrombosis, and endocarditis. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve dysfunction and according to the corresponding category.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Bioprosthetic Valve Failure According to VARC-3 Definitions
Zeitfenster: 30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure

Bioprosthetic valve failure will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve failure.

30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

1. Juli 2027

Studienabschluss (Geschätzt)

1. Juni 2032

Studienanmeldedaten

Zuerst eingereicht

19. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. September 2026

Zuerst gepostet (Tatsächlich)

8. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren